Merck, a leading force in science and technology, has introduced a groundbreaking innovation in genetic stability testing: the Aptegra™ CHO genetic stability assay. This revolutionary technology leverages the power of whole genome sequencing and bioinformatics to streamline and accelerate biosafety evaluation, propelling clients to commercial production with unprecedented speed.
Traditionally, CHO genetic stability testing relied on a cumbersome and time-consuming battery of assays. Aptegra™ disrupts this paradigm by consolidating five distinct assays and four disparate technologies into a single, next-generation sequencing-based platform. This streamlined approach slashes testing time by 66% and reduces costs by 43% compared to conventional methods.
Merck’s commitment to innovation in biosafety testing underscores its dedication to empowering clients with cutting-edge solutions that expedite the delivery of life-changing therapies to patients. The company’s global network of biosafety testing facilities provides comprehensive support to clients worldwide, ensuring the highest standards of quality and compliance.
A testament to Merck’s commitment to digital transformation, Aptegra™ joins a suite of transformative digital technologies developed by the company. AIDDISON™, an AI-driven platform, harnesses generative design and predictive synthesis planning to identify promising drug candidates and mitigate late-stage failures. Furthermore, Merck’s Bio4C® Software Suite seamlessly combines data analytics, automation, and control software for GMP manufacturing, empowering clients with unparalleled capabilities.
Merck’s unwavering investment in innovation and its dedication to client success position it as a trailblazer in the pharmaceutical industry. With the launch of Aptegra™ and its portfolio of cutting-edge digital technologies, Merck continues to drive the future of biosafety testing and empower clients to bring life-saving therapies to patients faster than ever before.
